PepGen
PepGen secures $112.5m financing to advance muscular dystrophy therapies
The funding round included existing investors RA Capital Management, Oxford Sciences Innovation (OSI) and CureDuchenne Ventures and a host of new investors.
The funding round included existing investors RA Capital Management, Oxford Sciences Innovation (OSI) and CureDuchenne Ventures and a host of new investors.